OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 sep 2010 - 22:04
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces agreement with US-based pharmaceutical company on its controlled release technology
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery company, announces today that it has signed a feasibility agreement with a US-based pharmaceutical company relating to the use of OctoPlus’ controlled release technology.
Under the contract announced today, OctoPlus will develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive®. If the evaluation is successful, the companies may decide to enter into a full process development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.
Datum laatste update: 02 september 2024